[ Impact of CCND1 A870 G polymorphism on acute adverse events in <font color="blue">postoperative_4</font> <font color="blue">rectal_4</font> <font color="blue">cancer_4</font> <font color="blue">patients_4</font> <font color="blue">treated_2</font> <font color="blue">with_2</font> <font color="blue">adjuvant_2</font> <font color="blue">concurrent_2</font> <font color="blue">chemoradiotherapy_2</font> <font color="blue">]_2</font> . 
<br>
<br> OBJECTIVE The purpose of this study was to investigate the association between single nucleotide polymorphism ( SNP ) of CCND1 A870 G and acute adverse events ( AEs ) in <font color="blue">postoperative_5</font> <font color="blue">rectal_5</font> <font color="blue">cancer_5</font> <font color="blue">patients_5</font> <font color="blue">who_2</font> <font color="blue">received_2</font> <font color="blue">capecitabine_2</font> <font color="blue">-_2</font> <font color="blue">based_2</font> <font color="blue">postoperative_2</font> <font color="blue">chemoradiotherapy_2</font> <font color="blue">(_2</font> <font color="blue">CRT_2</font> <font color="blue">)_2</font> <font color="blue">._2</font> <font color="blue">
<br>_1</font> METHODS <font color="blue">Four_7</font> <font color="blue">hundred_7</font> <font color="blue">patients_7</font> <font color="blue">with_7</font> <font color="blue">stage_7</font> <font color="blue">II_7</font> <font color="blue">and_7</font> <font color="blue">III_7</font> <font color="blue">rectal_7</font> <font color="blue">cancer_7</font> <font color="blue">received_5</font> <font color="blue">postoperative_5</font> <font color="blue">CRT_5</font> <font color="blue">of_5</font> <font color="blue">capecitabine_5</font> <font color="blue">with_5</font> <font color="blue">or_5</font> <font color="blue">without_5</font> <font color="blue">oxaliplatin_5</font> <font color="blue">were_1</font> <font color="blue">accumulated_1</font> <font color="blue">and_1</font> <font color="blue">prostectively_1</font> <font color="blue">studied_1</font> <font color="blue">in_1</font> <font color="blue">this_1</font> <font color="blue">study_1</font> <font color="blue">._1</font> <font color="blue">The_1</font> <font color="blue">patients_2</font> <font color="blue">were_2</font> <font color="blue">randomly_2</font> <font color="blue">divided_2</font> <font color="blue">into_2</font> <font color="blue">two_2</font> <font color="blue">groups_2</font> <font color="blue">._2</font> <font color="blue">Two_4</font> <font color="blue">hundred_4</font> <font color="blue">and_4</font> <font color="blue">twenty_4</font> <font color="blue">-_4</font> <font color="blue">eight_4</font> <font color="blue">patients_4</font> <font color="blue">were_1</font> <font color="blue">treated_1</font> <font color="blue">with_1</font> <font color="blue">concurrent_1</font> <font color="blue">capecitabine_1</font> <font color="blue">and_1</font> <font color="blue">radiotherapy_1</font> <font color="blue">(_1</font> <font color="blue">Cap_1</font> <font color="blue">-_1</font> <font color="blue">CRT_1</font> <font color="blue">)_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">172_2</font> <font color="blue">patients_2</font> <font color="blue">were_1</font> <font color="blue">treated_1</font> <font color="blue">with_1</font> <font color="blue">capecitabine_1</font> <font color="blue">and_1</font> <font color="blue">oxaliplatin_1</font> <font color="blue">plus_1</font> <font color="blue">radiotherapy_1</font> <font color="blue">(_1</font> <font color="blue">Cap_1</font> <font color="blue">-_1</font> <font color="blue">Oxa_1</font> <font color="blue">-_1</font> <font color="blue">CRT_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> Adverse events were graded according to the Common Terminology Criteria for Adverse Events , v. 3.0 ( CTCAE v3.0 ) . The <font color="blue">genotype_1</font> <font color="blue">of_1</font> <font color="blue">CCND1_1</font> <font color="blue">A870_1</font> <font color="blue">G_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">patients_1</font> was detected by polymerase chain reaction - based restriction fragment length polymorphism ( PCR - RFLP ) analysis . The associations between the SNP and acute AEs were indicated by odds ratios ( ORs ) and 95% confidence intervals ( CIs ) , which were computed with logistic regression model . 
<br> RESULTS A total of <font color="blue">136_2</font> <font color="blue">patients_2</font> <font color="blue">presented_1</font> <font color="blue">severe_1</font> <font color="blue">AEs_1</font> <font color="blue">._1</font> Among them the frequencies of the three genotypes GG , GA and AA were 16.9% , 50.7% and 32.4% , compared with 24.6% , 48.1% and 27.3% , respectively , among the <font color="blue">patients_1</font> <font color="blue">without_1</font> <font color="blue">severe_1</font> <font color="blue">AEs_1</font> <font color="blue">._1</font> Diarrhea was the most common AE , and <font color="blue">severe_1</font> <font color="blue">diarrhea_1</font> <font color="blue">occurred_1</font> <font color="blue">in_1</font> <font color="blue">109_1</font> <font color="blue">patients_1</font> <font color="blue">._1</font> The frequencies of the three genotypes GG , GA and AA were <font color="blue">15.6%_1</font> <font color="blue">,_1</font> <font color="blue">47.7%_1</font> <font color="blue">and_1</font> <font color="blue">36.7%_1</font> <font color="blue">among_1</font> <font color="blue">these_1</font> <font color="blue">patients_1</font> <font color="blue">,_1</font> compared with 24.4% , 49.5% and 26.1% , respectively , among <font color="blue">patients_1</font> <font color="blue">without_1</font> <font color="blue">severe_1</font> <font color="blue">diarrhea_1</font> <font color="blue">._1</font> Multivariate logistic regression analysis showed a 1.66-fold increased risk for severe diarrhea in <font color="blue">patients_1</font> <font color="blue">with_1</font> <font color="blue">AA_1</font> <font color="blue">genotype_1</font> ( 95%CI 1.03 - 2.67 , P = 0.038 ) compared with the <font color="blue">cases_1</font> <font color="blue">with_1</font> <font color="blue">GG_2</font> <font color="blue">or_2</font> <font color="blue">GA_2</font> <font color="blue">genotypes_2</font> <font color="blue">._2</font> Stratified analysis showed that in the <font color="blue">Cap_1</font> <font color="blue">-_1</font> <font color="blue">Oxa_1</font> <font color="blue">-_1</font> <font color="blue">CRT_1</font> <font color="blue">group_1</font> <font color="blue">,_1</font> <font color="blue">patients_2</font> <font color="blue">with_2</font> <font color="blue">AA_2</font> <font color="blue">genotype_2</font> showed a 2.34-fold increased risk for severe diarrhea ( 95%CI 1.16 - 4.76 , P = 0.018 ) compared with those with <font color="blue">GG_1</font> <font color="blue">or_1</font> <font color="blue">GA_1</font> <font color="blue">genotypes_1</font> <font color="blue">,_1</font> but in the <font color="blue">Cap_1</font> <font color="blue">-_1</font> <font color="blue">CRT_1</font> <font color="blue">group_1</font> <font color="blue">,_1</font> the SNP was not associated with the risk of severe diarrhea . 
<br> CONCLUSIONS The genetic polymorphism of CCND1 A870 G might be a potential biomarker for predicting acute AEs in <font color="blue">postoperative_2</font> <font color="blue">stage_2</font> <font color="blue">II_2</font> <font color="blue">and_2</font> <font color="blue">III_2</font> <font color="blue">rectal_2</font> <font color="blue">cancer_2</font> <font color="blue">patients_2</font> treated with adjuvant concurrent chemoradiotherapy of capecitabine and oxaliplatin .